{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:46:33Z","timestamp":1792683993957,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"abstract":"\n Importance<\/jats:title>\n \n Postoperative pain management in otolaryngology requires balancing effective analgesia while minimizing adverse effects, such as opioid-related complications. Suzetrigine is a first-in-class selective voltage-gated sodium channel (Na\n V<\/jats:sub>\n 1.8) inhibitor that has been recently approved by the US Food and Drug Administration. Suzetrigine selectively inhibits Na\n V<\/jats:sub>\n 1.8 channels expressed in peripheral nociceptive neurons, thereby reducing pain signaling without the respiratory depression, sedation, or misuse potential associated with opioids. This review summarizes the pharmacology, efficacy, safety profile, limitations, and potential applications of suzetrigine in otolaryngology.\n <\/jats:p>\n <\/jats:sec>\n \n Observations<\/jats:title>\n Prospective clinical trials consist of 2 phase 2 randomized clinical trials, 2 phase 3 randomized placebo-controlled trials, and 1 phase 3 open-label study involving more than 3000 patients. Across abdominoplasty and bunionectomy pain models, suzetrigine demonstrated superior analgesia compared with placebo and mixed efficacy comparable to hydrocodone\/acetaminophen. The drug was generally well tolerated, with adverse event rates similar to placebo and no significant respiratory, cardiac, or sedating adverse effects reported. Additionally, 1 retrospective cohort study has reported results in patients undergoing free flap reconstruction and transoral robotic surgery.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Suzetrigine is a promising nonopioid analgesic with demonstrated efficacy compared to placebo in acute postoperative pain and a favorable safety profile. In otolaryngology, suzetrigine may serve as an adjunct to multimodal analgesia and an opioid-sparing option for patients with contraindications to traditional analgesics, opioid use disorder, or procedures that are expected to have high opioid utilization such as tonsillectomy, sleep surgery, and major head and neck surgery. Future studies in otolaryngology are warranted to evaluate whether suzetrigine can meaningfully reduce postoperative opioid exposure without compromising analgesic effectiveness.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoto.2026.3308","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:30:33Z","timestamp":1792683033000},"source":"Crossref","is-referenced-by-count":0,"title":["Na\n V<\/sub>\n 1.8 Inhibition and the Future of Nonopioid Analgesia in Otolaryngology"],"prefix":"10.1001","author":[{"given":"Tristan","family":"Tham","sequence":"first","affiliation":[{"name":"Division of Comprehensive Otolaryngology, Department of Otolaryngology\u2013Head and Neck Surgery, Stanford University, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan B.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pain Medicine, Department of Anesthesiology, Stanford University, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uchechukwu C.","family":"Megwalu","sequence":"additional","affiliation":[{"name":"Division of Comprehensive Otolaryngology, Department of Otolaryngology\u2013Head and Neck Surgery, Stanford University, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"5","key":"orv260004r1","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1213\/ANE.0000000000002458","article-title":"Chronic opioid use after surgery: implications for perioperative management in the face of the opioid epidemic.","volume":"125","author":"Hah","year":"2017","journal-title":"Anesth Analg"},{"issue":"4","key":"orv260004r2","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/0194599820947013","article-title":"Nonopioid, multimodal analgesia as first-line therapy after otolaryngology operations: primer on nonsteroidal anti-inflammatory drugs (NSAIDs).","volume":"164","author":"Cramer","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"orv260004r3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/0194599819852328","article-title":"Postoperative bleeding associated with ibuprofen use after tonsillectomy: a meta-analysis.","volume":"161","author":"Stokes","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"orv260004r5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain.","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther"},{"issue":"7","key":"orv260004r6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nrn1938","article-title":"The distribution and targeting of neuronal voltage-gated ion channels.","volume":"7","author":"Lai","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"orv260004r7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coph.2007.09.007","article-title":"Sodium channels and nociception: recent concepts and therapeutic opportunities.","volume":"8","author":"Krafte","year":"2008","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"orv260004r8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1152\/physrev.00052.2017","article-title":"The role of voltage-gated sodium channels in pain signaling.","volume":"99","author":"Bennett","year":"2019","journal-title":"Physiol Rev"},{"issue":"6562","key":"orv260004r9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/379257a0","article-title":"A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons.","volume":"379","author":"Akopian","year":"1996","journal-title":"Nature"},{"key":"orv260004r10","doi-asserted-by":"publisher","DOI":"10.1177\/1744806919858801","article-title":"Nav1.7 and Nav1.8: role in the pathophysiology of pain.","volume":"15","author":"Hameed","year":"2019","journal-title":"Mol Pain"},{"issue":"5","key":"orv260004r11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of NaV1.8 with VX-548 for acute pain.","volume":"389","author":"Jones","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"orv260004r12","first-page":"1085","article-title":"Suzetrigine, a nonopioid Na V 1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials.","volume":"142","author":"Bertoch","year":"2025","journal-title":"Anesthesiology"},{"key":"orv260004r13","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2147\/JPR.S509144","article-title":"Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain.","volume":"18","author":"McCoun","year":"2025","journal-title":"J Pain Res"},{"key":"orv260004r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2026.2673","article-title":"Suzetrigine for postoperative pain in head and neck free flap or transoral robotic surgery.","author":"Bestourous","year":"2026","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"orv260004r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2026.2664","article-title":"Suzetrigine in head and neck surgery: a new frontier in opioid stewardship.","author":"Mukkara","year":"2026","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"orv260004r18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2165\/00003088-199733030-00005","article-title":"Pharmacokinetic optimisation of opioid treatment in acute pain therapy.","volume":"33","author":"Upton","year":"1997","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"orv260004r19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pain.2013.08.013","article-title":"Faster, higher, stronger?\u2014evidence for formulation and efficacy for ibuprofen in acute pain.","volume":"155","author":"Moore","year":"2014","journal-title":"Pain"},{"issue":"6","key":"orv260004r20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/ALN.0000000000005465","article-title":"Suzetrigine: first in a new class of nonopioid analgesics for acute pain.","volume":"142","author":"Rathmell","year":"2025","journal-title":"Anesthesiology"},{"issue":"3","key":"orv260004r22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/rapm-2024-106068","article-title":"Opioid consumption in the first 30 days after surgery was independently associated with new persistent opioid use.","volume":"51","author":"Ervin-Sikhondze","year":"2026","journal-title":"Reg Anesth Pain Med"},{"issue":"7","key":"orv260004r23","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.5664\/jcsm.9978","article-title":"Incidence and risk factors of chronic opioid use after sleep apnea surgery.","volume":"18","author":"Abdelwahab","year":"2022","journal-title":"J Clin Sleep Med"},{"issue":"2_suppl","key":"orv260004r24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1177\/0194599821996297","article-title":"Clinical practice guideline: opioid prescribing for analgesia after common otolaryngology operations.","volume":"164","author":"Anne","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"14","key":"orv260004r25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jama.2015.12397","article-title":"Addressing the opioid epidemic.","volume":"314","author":"Nelson","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"orv260004r26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1213\/ANE.0000000000003434","article-title":"Society of Anesthesia and Sleep Medicine guideline on intraoperative management of adult patients with obstructive sleep apnea.","volume":"127","author":"Memtsoudis","year":"2018","journal-title":"Anesth Analg"},{"issue":"8","key":"orv260004r27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1001\/jamaoto.2019.1448","article-title":"Perioperative care of patients with obstructive sleep apnea undergoing upper airway surgery: a review and consensus recommendations.","volume":"145","author":"Ravesloot","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"5","key":"orv260004r28","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1177\/0194599818757959","article-title":"Opioid prescribing patterns among otolaryngologists.","volume":"158","author":"Schwartz","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"orv260004r29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1177\/0194599818778276","article-title":"Persistent postoperative opioid use in older head and neck cancer patients.","volume":"160","author":"Saraswathula","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"orv260004r30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1177\/0194599820960137","article-title":"Implications of treatment modality on chronic opioid use following treatment for head and neck cancer.","volume":"164","author":"Bollig","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"key":"orv260004r31","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-021-00508-y","article-title":"Chronic opioid use following surgery for head and neck cancer patients undergoing free flap reconstruction.","author":"Hinther","year":"2021","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"8","key":"orv260004r32","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1177\/00034894211045771","article-title":"Long-term opioid use in post-surgical management of patients with head and neck cancer.","volume":"131","author":"Wang","year":"2022","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"3","key":"orv260004r33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamaoto.2016.2981","article-title":"Optimal perioperative care in major head and neck cancer surgery with free flap reconstruction: a consensus review and recommendations from the Enhanced Recovery After Surgery Society.","volume":"143","author":"Dort","year":"2017","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"orv260004r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2025.112440","article-title":"Effect of otolaryngology analgesia guidelines on opioid prescribing in pediatric tonsillectomy.","volume":"195","author":"Kistler","year":"2025","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"9","key":"orv260004r35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008659.pub3","article-title":"Single dose oral analgesics for acute postoperative pain in adults \u2014 an overview of Cochrane reviews.","volume":"2015","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"orv260004r36","doi-asserted-by":"publisher","first-page":"j1909","DOI":"10.1136\/bmj.j1909","article-title":"Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.","volume":"357","author":"Bally","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"orv260004r37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ehjcvp\/pvac015","article-title":"Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.","volume":"8","author":"Obeid","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"orv260004r38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00784-017-2272-2","article-title":"Oral pregabalin for acute pain relief after cervicofacial surgery: a systematic review.","volume":"22","author":"Li\u00e9bana-Hermoso","year":"2018","journal-title":"Clin Oral Investig"},{"issue":"11","key":"orv260004r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2018.0282","article-title":"Effect of perioperative gabapentin use in patients undergoing head and neck mucosal surgery.","volume":"144","author":"Townsend","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"8","key":"orv260004r40","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000002350","article-title":"Gabapentin decreases narcotic usage: enhanced recovery after surgery pathway in free autologous breast reconstruction.","volume":"7","author":"Fan","year":"2019","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"8","key":"orv260004r41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2020.1170","article-title":"Multimodal analgesia and perioperative opioid requirements in head and neck surgery with free flap.","volume":"146","author":"Vu","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"orv260004r4","unstructured":"US Food and Drug Administration. FDA approves novel non-opioid treatment for moderate to severe acute pain. Accessed June 2, 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain"},{"key":"orv260004r16","unstructured":"Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR). ClinicalTrials.gov identifier: NCT06176196. Updated October 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06176196"},{"key":"orv260004r17","unstructured":"Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN). ClinicalTrials.gov identifier: NCT05660538. Updated July 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05660538"},{"key":"orv260004r21","unstructured":"Vertex Pharmaceuticals Incorporated. Vertex announces FDA approval of JOURNAVX (suzetrigine), a first-in-class treatment for adults with moderate-to-severe acute pain. Published January 30, 2025. Accessed June 1, 2026. https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-fda-approval-journavxtm-suzetrigine-first-class"}],"container-title":["JAMA Otolaryngology\u2013Head & Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2855836\/jamaotolaryngology_tham_2026_rv_260004_1792505835.76272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:30:37Z","timestamp":1792683037000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2855836"}},"subtitle":["A Narrative Review"],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2026.3308","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,22]]}}}